Saizen Articles
Merck Serono’s ready-to-use formulation of Saizen recommended for approval in Europe
16 November 2010
Sales up 18% in 1st qtr for Novo Nordisk
5 May 2009
Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales
27 April 2009
Novo Nordisk profits up 13% on insulin sales
9 February 2009
Novo Nordisk's 2nd-qtr 2008 profit falls 32%
18 August 2008
Merck Serono to grow Japanese business
4 August 2008
Novo Nordisk's nine-month profit soars 60%
12 November 2007
US FDA clears Merck KGaA's easypod
12 November 2007
Norditropin gets FDA OK for Noonan syndrome
18 June 2007
Novo Nordisk's 1st-qtr 2007 profit rises 41%
14 May 2007
Polish biotech Bioton buys Biopartners
26 March 2007
Novo Nordisk growing in Japan
19 March 2007
Merck Serono debuts easypod injection device
5 February 2007
Mixed results for Novo Nordisk in 3rd-qtr 2006
6 November 2006
Serono's 3rd-qtr 2006 sales rise 8.4% on Rebif
30 October 2006
Serono's net income up 8% in 2nd-qtr
31 July 2006
Cambridge Labs' Valtropin cleared in EU
15 May 2006
Serono 4th qtr shows profit but disappoints
13 February 2006
One-time provisional charge blights Serono's 1st-qtr results, putting firm into a loss
22 April 2005
BioPartners signs 10-year license accord with The Medical House
28 February 2005
Novo Nordisk's Norditropin NordiFlex debuts in USA
31 January 2005
Serono's Saizen also available for adult GHD
17 January 2005
New use for Novo Nordisk's Norditropin
15 November 2004
Novo Nordisk to appeal court's hGH patent rulings
13 September 2004
Serono's 2nd-qtr net income jumps 26%
2 August 2004
Serono infertility APIs to be made in Spain
19 July 2004
Serono's 1st-qtr income rockets 76.4%
26 April 2004
Serono beats expectations with 3rd-qtr 2003 net income up 48%
3 November 2003
Novo Nordisk
18 August 2003
Serono raises 2003 forecast; 2nd-qtr figs
4 August 2003
Novo Nordisk's Norditropin cleared by EC
7 July 2003
New use for Norditropin backed in EU
31 March 2003
Serono's cool.click device cleared in EU
10 June 2002
Serono reports 10.4% 1st-qtr sales increase
29 April 2002
Profit warning at Novo Nordisk
22 April 2002
Pretax profits up 25% at Novo Nordisk
18 February 2002
Pretax profits up 33% at Novo Nordisk
7 November 2001
Serono reports disappointing sales
31 October 2001
Extended labeling for Serono's Saizen approved in EU
16 August 2001
Novo Nordisk sales climb 21%
9 May 2001
Serono makes strong start to 2001
2 May 2001
Needle-free hGH approved for HIV in USA
5 April 2001
Novo Nordisk sales increase 27%
21 February 2001
Novo and Pharmacia settle hGH dispute
14 November 2000
Operating profit up 34% at Novo Nordisk
15 August 2000
Needle-free hGH from Serono approved in USA
26 June 2000
US approval for Novo Nordisk's Norditropin
21 June 2000
"Robust" 1st qtr for Novo Nordisk
5 May 2000
Novo gains Japanese approval for Norditropin SimpleXx
23 March 2000
Novo Nordisk sales increase 17%
21 February 2000
Novo Nordisk settles Lilly patent dispute
2 February 2000
Novo Nordisk pretax profits increase 11%
12 November 1999
EU OKs NovoRapid and Norditropin SimpleXx
16 September 1999
Novo Nordisk sales rise 13%, signs pact with Japan's Takeda
12 August 1999
Novo seeks US go-ahead for liquid hGH (updated)
6 July 1999
Novo files for hGH liquid form in USA
2 July 1999
Novo Nordisk posts solid first-quarter sales
13 May 1999
1st qtr net income up 111% at Ares-Serono
30 April 1999
Novo liquid hGH approved in Denmark
29 March 1999
Novo Nordisk health care sales rise 8%
19 February 1999
Serono Launches Growth Hormone Patient Registry
17 December 1998
Strong Rises In Sales, Net Income At Novo Nordisk
20 February 1998
Strong $ Hits Ares-Serono's European Growth
16 January 1998
Yamanouchi 1st Half Net Income Up 15%
14 November 1997
Nine-Month Sales Up 15% At Novo Nordisk
14 November 1997
Strong Earnings Growth At Yamanouchi
30 May 1997
1st-Qtr Profits Slow At Novo Nordisk
26 May 1997
New CPAC Approvals Include Two NCEs
7 April 1997
Novo Gets Go-Ahead For hGH
19 March 1997
Novo Nordisk's US Launch Plans For Norditropin
13 January 1997
Novo's Norditropin Cleared In USA
6 January 1997
Novo Nordisk' Health Care Business Sees Best Growth
18 November 1996
Serono Labs' Saizen Approved In USA
21 October 1996
Genentech Files Against Novo Nordisk On Insulin
7 October 1996
Novo Nordisk On Target For 1996
19 August 1996
Sales Growth At Yamanouchi Led By Gaster
10 June 1996
Profits Rise At Novo Nordisk In 1st Qtr
20 May 1996
Serono's Saizen Approvable, Says FDA
6 May 1996
Currency Impact Hits Novo Nordisk
18 March 1996
Tokyo Stock Comment
18 March 1996
Strong 9 Months Earnings Growth For Novo Nordisk
20 November 1995
Yamanouchi Looks To New Products For Growth
23 October 1995
Strong Sales Growth For Biotechnology General
11 September 1995
Genentech/Bio-Technology General's BioTropin case
21 August 1995
Novo Nordisk's First Half
14 August 1995
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
